$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
艾伏尼布在国内能买到吗
2025-10-19 11:44:20
Check Details
艾伏尼布(ivosidenib)的副作用和不良反应
2025-10-19 11:44:20
Check Details
艾伏尼布(ivosidenib)的用法用量:用药指南,剂量调整,
2025-10-19 11:44:20
Check Details
艾伏尼布的作用与功效
2025-10-19 11:44:20
Check Details
艾伏尼布(ivosidenib)的详细说明书:作用与功效,用法用量,副作用,注意事项
2025-10-19 11:44:20
Check Details
艾伏尼布的副作用如何缓解
2025-10-19 11:44:20
Check Details
施维雅宣布FDA批准拓舒沃(艾伏尼布片)用于治疗IDH1突变的复发或难治性(R/R)骨髓增生异常综合征(MDS)
2025-10-19 11:44:20
Check Details
FDA批准佩米替尼(pemigatinib)作为首个治疗既往接受过治疗、无法切除的局部晚期或转移性胆管癌成人患者的靶向治疗药物
2025-10-19 11:44:20
Check Details
u200cFDA批准佩米替尼(pemigatinib)作为首个治疗FGFR1重排髓系/淋巴系肿瘤的靶向治疗药物
2025-10-19 11:44:20
Check Details
佩米替尼(pemigatinib)的用法用量:用药指南,剂量调整,特殊人群用药,用药注意事项
2025-10-19 11:44:20
Check Details
佩米替尼(pemigatinib)的副作用和常见不良反应
2025-10-19 11:44:20
Check Details
佩米替尼(pemigatinib)中文说明书
2025-10-19 11:44:20
Check Details
1
2
...
48
49
50
51
52
53
54
...
4162
4163
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Selpercatinib Traditional Approval for RET Fusion Solid Tumors: Weight-Based Adults, BSA-Based Pediatrics, Monitor Liver, BP, QT
2
Atezolizumab Plus mFOLFOX as Adjuvant Therapy for Stage III dMMR Colon Cancer: ATOMIC DFS HR 0.50
3
Tucatinib Plus Trastuzumab and Pertuzumab Maintenance in HER2-Positive Advanced Breast Cancer: HER2CLIMB-05 Median PFS 24.9 Months
4
Zenocutuzumab (Bizengri) for NRG1 Fusion Solid Tumors: HER2×HER3 Bispecific, 750mg Q2W, NSCLC/Pancreas/Cholangiocarcinoma
5
Pemigatinib for FGFR2 Cholangiocarcinoma and FGFR1 Hematologic Use: First-Line Data, 21-Day Dosing, Phosphate and Ocular Management
6
Dabrafenib (Tafinlar) Complete Guide: Indications, Dosing, Combination Therapy and Safety
7
Binimetinib plus Encorafenib for BRAF‑Mutant Melanoma
8
Adagrasib (Krazati) for KRAS G12C: NSCLC Dosing, Titration, and CRC Regulatory Update
9
Ceritinib for ALK-Positive NSCLC: Indication, Dosing, and Safety Management
10
Enzalutamide for Prostate Cancer: Managing Fatigue, Dizziness, Hypertension, and Serious Neurocardiovascular Risks
11
Tamoxifen Long-Term Safety: Vigilance for Thrombosis and Endometrial Risks
12
Acoramidis for ATTR-CM: Disease Progression Is Not Equivalent to Drug Resistance